Celadon's objective is to improve the quality of life for the most vulnerable people by producing cannabis-based medications.
Celadon Pharmaceuticals has raised $2.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2024.
Celadon Pharmaceuticals is headquartered in London, United Kingdom.
Celadon's objective is to improve the quality of life for the most vulnerable people by producing cannabis-based medications.
Celadon Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Celadon Pharmaceuticals — Funding & Investors." VCBacked, May 10, 2024, https://www.vcbacked.co/company/celadon-pharmaceuticals. Accessed August 15, 2026.
VCBacked. (2024). Celadon Pharmaceuticals — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/celadon-pharmaceuticals
{{cite web |title=Celadon Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/celadon-pharmaceuticals |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated